Germline PGX molecular testing
Ended Awarded Last action
- Contract number
- 36C10X24N0227
- Awardee
-
Fulgent Therapeutics LLC UEI JVZDRESJLD82 Part of Fulgent Genetics, Inc.
- Awarding agency
-
VA Strategic Acquisition Center Frederick
Headquarters, Department of Veterans Affairs
- Obligated
- $2,949,000
Award facts
- Opportunity
-
- Q301--Germline PGx Services (VA-24-00021530) Pre-Solicitation · Posted Jun 5, 2024
- Contract value 100% obligated
- $2,949,000.00 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Frederick, MD 21703, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $100,000 | |
| Funding Only Action | $549,000 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $2,300,000 |
About this award
The Department of Veterans Affairs Strategic Acquisition Center Frederick awarded a $2.949 million delivery order for germline pharmacogenomic molecular testing to Fulgent Therapeutics LLC (doing business as Fulgent Diagnostics) on September 30, 2024. This supplemental agreement represents work within scope and is issued without a set-aside designation, indicating open competition. The work will be performed in Frederick, Maryland, with an ultimate completion date of September 29, 2029. This delivery order is issued under Fulgent Therapeutics' larger $99.032 million indefinite delivery contract with the VA Strategic Acquisition Center, which provides national access to germline genetic testing across oncology, medical genetics, and pharmacogenomics programs. Fulgent Therapeutics is a subsidiary of Fulgent Genetics, Inc., based in El Monte, California, and specializes in advanced genetic testing and genomic sequencing services.
The award supports the VA's healthcare mission by providing specialized pharmacogenomic testing capabilities that enable personalized medication management for veteran populations. Germline pharmacogenomic testing identifies genetic variations affecting drug metabolism and response, allowing clinicians to optimize pharmaceutical treatments and reduce adverse drug events. Fulgent Therapeutics has demonstrated capability across multiple federal healthcare agencies, including the CDC, Army Medical Command, and HHS, with contract values ranging from routine purchases to substantial genomic sequencing programs. The firm-fixed-price delivery order structure ensures cost predictability while the broader IDC vehicle enables the VA to flexibly task order services across its healthcare system through 2029.
Quick answers
Who was awarded contract 36C10X24N0227?
36C10X24N0227 was awarded to Fulgent Therapeutics LLC by VA Strategic Acquisition Center Frederick (Headquarters) on September 30, 2024.
How much is contract 36C10X24N0227 worth?
The government has obligated $2,949,000 on 36C10X24N0227.
Is contract 36C10X24N0227 an order under another contract?
Yes. 36C10X24N0227 is a delivery order under 36C10X24D0028, an indefinite delivery contract, on Germline PGx Services.
Was contract 36C10X24N0227 competed?
The extent of competition for 36C10X24N0227 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award